Robert J. Motzer, MD, on Research Areas of Focus in Renal Cell Carcinoma

Video

The medical oncologist at Memorial Sloan Kettering Cancer Center discussed areas of research in renal cell carcinoma that he thinks should be further explored.

In an interview with CancerNetwork®, Robert J. Motzer, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, highlighted areas of research within renal cell carcinoma (RCC) which he believes should be studied further.

Transcription:

I think we’ve made tremendous headway with [immuno-oncology] combinations. I’m hoping that some of the drugs with novel mechanism of actions like [belzutifan; MK-6482], will bear fruit and advance our therapeutic options. And I think the other area that really needs to be explored is a better look and a deep dive into the underlying tumor biology and why some patients respond to 1 medication and some respond to another. Are there different targets that we can identify within the tumors? That’'\s an area now that really needs to be explored.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content